(Q37571461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

review article

1 reference

title

Urine markers in monitoring for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jan Bouchal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

T Jamaspishvili

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

I Khomeriki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

V Student

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Z Kolar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

4 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

12-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

Prostate-specific antigen: update 2006.

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Repeat prostate biopsy: who, how and when?. a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urinary markers for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urine markers as possible tools for prostate cancer screening: review of performance characteristics and practicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

DNA-based detection of prostate cancer in urine after prostatic massage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Annexins: linking Ca2+ signalling to membrane dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Identification and proteomic profiling of exosomes in human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Expression and prognostic relevance of annexin A3 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Molecular PCA3 diagnostics on prostatic fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Molecular beacons: a novel DNA probe for nucleic acid and protein studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Recurrent gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Molecular biology of the Ets family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Role of the TMPRSS2-ERG gene fusion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Quantitative multi-gene expression profiling of primary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

The expression and significance of survivin mRNA in urinary bladder carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

The role of SPINK1 in ETS rearrangement-negative prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Preliminary evaluation of 5 alpha-reductase type 2 in urine as a potential marker for prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Trefoil factor 3 is overexpressed in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Use of thymosin beta15 as a urinary biomarker in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

DNA-based detection of prostate cancer in blood, urine, and ejaculates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Use of multiple biomarkers for a molecular diagnosis of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Clinical application of basic arginine amidase in human male urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urine detection of survivin and diagnosis of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urinary tissue factor levels in patients with bladder and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Diagnosis of Genito-Urinary Tract Cancer by Detection of Minichromosome Maintenance 5 Protein in Urine Sediments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.31

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19652665%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference